# A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH

> **NCT06675929** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 28 (actual)

## Conditions studied

- Compensated Liver Cirrhosis
- Metabolic Dysfunction Associated Steatohepatitis (MASH)

## Interventions

- **DRUG:** BI 770371
- **DRUG:** Placebo for BI 770371

## Key facts

- **NCT ID:** NCT06675929
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-20
- **Primary completion:** 2026-01-13
- **Final completion:** 2026-01-13
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06675929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06675929, "A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06675929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*